Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1163-1170. doi: 10.1051/medsci/2019231. Epub 2020 Jan 6.

[Developability assessment].

[Article in French; Abstract available in French from the publisher]

Author information

1
Biologics Research/Sanofi R&D, 13 quai Jules Guesde, 94403 Vitry-sur-Seine, France.
2
Biologics Drug Products Development/Sanofi R&D, 13 quai Jules Guesde, 94403 Vitry-sur-Seine, France.

Abstract

in English, French

The therapeutic antibodies and their by-products (antibody fragments, conjugated, etc.) establish one of the most dynamic biopharmaceutical market segments today. Due to their intrinsic properties of specificity towards their target, towards their flexible affinity and due to their stability, antibodies became therapeutic agents of the very first choice. One of the challenges of this sector is to create antibodies of very good quality, more and more quickly, while having less and less consequent development costs in fine.

PMID:
31903932
DOI:
10.1051/medsci/2019231

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center